AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$CRL

Charles River Laboratories (NYSE:CRL) exceeds Q3 2026 expectations

Charles River Laboratories reported Q3 2026 revenue of $982.7M, beating estimates by 2.3% and showing a 2.2% YoY decline. Adjusted EPS of $3.09 beat estimates by 4%. Management raised full-year adjusted EPS guidance to $11.45 at the midpoint. Operating and free cash flow margins improved YoY.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Charles River Laboratories (NYSE:CRL) exceeds Q3 2026 expectations — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CRLBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to drive short‑term buying pressure.

02

Market read

Earnings beat and guidance lift suggest a bullish outlook for CRL and its sector.

03

What to watch

Potential cost pressures or regulatory risks not addressed in the release.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Charles River Laboratories reported Q3 2026 results, beating revenue and EPS estimates and raising full‑year EPS guidance.

Company-level read

Ticker impact

$CRLBullishHigh confidence
Context

Q3 2026 revenue $982.7M beat estimates and EPS guidance raised to $11.45

Expected impact

likely upside as market prices in higher EPS expectations

Evidence & confidence

Both revenue and EPS beat consensus and management increased full-year EPS guidance, indicating improved profitability.

Market effects

Sector

Positive signal for the life‑science services sector.

Regional

U.S. biotech and pharma stocks may see modest gains.

Global

Limited to investors tracking U.S. healthcare earnings.

Counterpoint

What could challenge this read

If guidance is overly optimistic, the stock could face disappointment on future results.

Key entities

  • company
    Charles River Laboratories

    U.S. listed provider of preclinical and clinical laboratory services.

Read at source← All news

StoryCharles River Laboratories reports Q3 2026 earnings beat and raises 2026 outlook

Also covered by

6 outlets

Related articles

NOV 4
$CRLMedAI 8/10

Charles River Q3 2026 slides: organic growth returns but stock falls

Charles River Laboratories (CRL) reported Q3 2026 results with 4.7% organic revenue growth and non-GAAP EPS of $3.09, beating estimates. Despite this, shares fell 5.88% due to concerns over margin sustainability and delayed pricing power recovery. Revenue was $982.7M, with non-GAAP operating margin expanding to 23.0%. The DSA segment saw 5.9% organic growth, while Manufacturing grew 7.4% organically. Management expects pricing benefits to materialize in late 2027.

investing.com6 min
NOV 4
$CRLMedAI 8/10

Charles River Laboratories 2026: Revenue $982.73M, EPS $6.86— 10-Q Summary

Charles River Laboratories reported Q3 2026 revenue of $982.73M, down 2.2% YoY, while net income rose to $333.07M and EPS increased to $6.86. Management cited improving demand in Discovery and Safety Assessment, portfolio changes, and cost savings. Nine-month revenue declined 1.3%, with growth in microbial testing and China model sales. The company completed divestitures and acquisitions, targeting $300M in annual savings by 2026.

tradingview.com1 min
NOV 4
$CRLMed

Charles River Laboratories Lifts Annual Outlook- Update

Charles River Laboratories (CRL) raised its 2026 outlook, expecting revenue to decline 1.5%-2.0% (previously 2.5%-3.5%) and organic revenue to grow at least 1.5% (previously 0%-1%). EPS estimates increased to $8.15-$8.35 from $3.05-$3.35, with non-GAAP EPS at $11.35-$11.55. Q3 profit rose to $333.07M ($6.86/share) due to a $245.6M tax benefit, while revenue fell 2.1% to $982.732M. Shares dropped nearly 4% in pre-market trading.

rttnews.com2 min
NOV 4
$CRLHighAI 8/10

Charles River: Q3 Earnings Snapshot

Charles River Laboratories (CRL) reported Q3 net income of $333.1M, or $6.86 per share. Adjusted earnings were $3.09 per share, exceeding analyst estimates of $2.98 per share. Revenue was $982.7M, surpassing expectations of $956.8M. The company expects full-year earnings between $11.35 and $11.55 per share.

finance.yahoo.com2 min